U.S. markets closed
  • S&P 500

    4,188.43
    -44.17 (-1.04%)
     
  • Dow 30

    34,742.82
    -34.94 (-0.10%)
     
  • Nasdaq

    13,401.86
    -350.38 (-2.55%)
     
  • Russell 2000

    2,212.70
    -58.93 (-2.59%)
     
  • Crude Oil

    64.88
    -0.02 (-0.03%)
     
  • Gold

    1,836.80
    +5.50 (+0.30%)
     
  • Silver

    27.40
    -0.08 (-0.28%)
     
  • EUR/USD

    1.2137
    -0.0031 (-0.25%)
     
  • 10-Yr Bond

    1.6020
    +0.0250 (+1.59%)
     
  • GBP/USD

    1.4124
    +0.0135 (+0.96%)
     
  • USD/JPY

    108.8120
    +0.2300 (+0.21%)
     
  • BTC-USD

    55,288.86
    -2,606.17 (-4.50%)
     
  • CMC Crypto 200

    1,458.34
    -102.95 (-6.59%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    29,518.34
    +160.52 (+0.55%)
     

Soliton Stock Rallies After $22.60/Share Buyout From AbbVie

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • AbbVie Inc (NYSE: ABBV) is making an opportunistic play to boost the aesthetics business by adding a long-delayed body sculpting product into the fold.

  • AbbVie’s Allergan Aesthetics unit will pay 0 million in cash to scoop up Soliton Inc (NASDAQ: SOLY) and Resonic, its sound-wave device that improves the appearance of cellulite.

  • Under the terms of the transaction, Allergan Aesthetics will pay $22.60 per share in cash for each outstanding share of Soliton.

  • The body sculpting offering will help add some heft to the Allergan Aesthetics brand, which includes cosmetic Botox as its most visible product.

  • AbbVie propped up the aesthetics business as part of its $63 billion buyout of Allergan last year, keeping Botox’s therapeutic indications under the AbbVie brand.

  • Allergan Aesthetics already has a product in CoolSculpting Elite. Still, the Soliton pickup adds a non-invasive option in Resonic, which also holds approval in tattoo removal alongside lasers and improves the appearance of fibrotic scars.

  • Cosmetic Botox cleared $447 million in the first quarter, a 44.7% Y/Y increase. The unit, on the whole, made $1.14 billion in sales on the quarter. Meanwhile, the overall AbbVie business cleared more than $13 billion in sales on the quarter, led once again by Humira at $3.9 billion.

  • Price Action: SOLY shares are up 23.7% at $22.27, while ABBV shares are up 0.31% at $116.12 during the market trading session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.